Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
Holly Pacenta(Children's Hospital Colorado), Margaret E. Macy(Children's Hospital Colorado)
Cited by 53
Related Papers
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial
|The Lancet Oncology|2019|353
Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG)
|Neuro-Oncology|2022|136